- Home
- MDCX vs IGC Comparison
MDCX vs IGC Comparison
Compare MDCX & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDCX
- IGC
- Stock Information
- Founded
- MDCX 2008
- IGC 2005
- Country
- MDCX United States
- IGC United States
- Employees
- MDCX N/A
- IGC N/A
- Industry
- MDCX
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- MDCX
- IGC Health Care
- Exchange
- MDCX Nasdaq
- IGC Nasdaq
- Market Cap
- MDCX 50.8M
- IGC 39.8M
- IPO Year
- MDCX N/A
- IGC N/A
- Fundamental
- Price
- MDCX $2.41
- IGC $0.40
- Analyst Decision
- MDCX Strong Buy
- IGC Strong Buy
- Analyst Count
- MDCX 2
- IGC 2
- Target Price
- MDCX $23.50
- IGC $4.00
- AVG Volume (30 Days)
- MDCX 397.4K
- IGC 747.7K
- Earning Date
- MDCX 11-22-2025
- IGC 11-11-2025
- Dividend Yield
- MDCX N/A
- IGC N/A
- EPS Growth
- MDCX N/A
- IGC N/A
- EPS
- MDCX N/A
- IGC N/A
- Revenue
- MDCX N/A
- IGC $1,327,000.00
- Revenue This Year
- MDCX N/A
- IGC $3.54
- Revenue Next Year
- MDCX N/A
- IGC $15.12
- P/E Ratio
- MDCX N/A
- IGC N/A
- Revenue Growth
- MDCX N/A
- IGC 24.95
- 52 Week Low
- MDCX $1.79
- IGC $0.25
- 52 Week High
- MDCX $8.94
- IGC $0.50
- Technical
- Relative Strength Index (RSI)
- MDCX 50.21
- IGC 48.15
- Support Level
- MDCX $2.33
- IGC $0.38
- Resistance Level
- MDCX $2.70
- IGC $0.44
- Average True Range (ATR)
- MDCX 0.19
- IGC 0.02
- MACD
- MDCX -0.02
- IGC -0.00
- Stochastic Oscillator
- MDCX 44.23
- IGC 35.50
About MDCX Medicus Pharma Ltd. Common Stock
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.